BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
Mary J. van Helden, Seline A. Zwarthoff, Roel J. Arends, Inge Reinieren-Beeren et autres
Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. However, CD47 is ubiquitously expressed and mediates functional interactions …
nl (code pays fourni par la source)
20 citations
Journal for ImmunoTherapy of Cancer